In our validation cohort, early-stage (TNM stages I-II, tumor size less than 3 cm, single tumor nodule) HCC patients with high level of MACC1 protein immunostained also display a relative low OS than those diagnosed with late-stage HCC who carry high levels of MACC1 expression. This evidence concerns the gene MACC1 and hepatocellular carcinoma.